Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Exclusion Criteria

• •Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy in the study eye (predominantly classic CNV can however only be included if the subject had up to 3 prior PDT treatments)
• •Treatment with verteporfin in the non-study eye less than 7 days preceding Day 0
• •Previous participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)
• •Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye
• •Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Day 0
• •History of vitrectomy, submacular surgery, or other surgical intervention for AMD in the study eye
• •Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals)